Inerta

Isotretinoin, the active ingredient in Inerta, is a retinoid presented as an oral formulation for oral use. It treats severe nodular acne and acne vulgaris in patients who have not responded adequately to conventional therapies.

GNH USA supplies Inerta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inerta, a retinoid, is used in dermatologic conditions that involve excessive sebum production and follicular hyperkeratinisation.

Severe nodular acne: reduces inflammatory lesions and prevents new nodule formation. Acne vulgaris: decreases comedones and inflammatory papules. Recalcitrant acne: provides therapeutic benefit when other systemic agents have failed.

Isotretinoin may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dry skin and lips: increased transepidermal water loss. - Elevated liver enzymes: mild, transient hepatic impact. - Hypertriglyceridaemia: rise in serum triglyceride levels. - Musculoskeletal discomfort: joint or muscle aches. - Photosensitivity: heightened skin reaction to sunlight. - Mood changes: occasional irritability or depressive symptoms.

Serious or Rare Side Effects: - Severe hepatotoxicity: marked elevation of liver enzymes or jaundice. - Pseudotumor cerebri: increased intracranial pressure presenting with headache and visual changes. - Pancreatitis: acute abdominal pain with elevated pancreatic enzymes. - Severe depression or suicidal ideation: emergent psychiatric symptoms. - Bone growth disturbances: premature epiphyseal closure in adolescents. - Severe hyperlipidaemia: triglycerides > 500 mg/dL requiring medical intervention.

Isotretinoin requires careful monitoring due to its potent pharmacologic profile.

Pregnancy contraindication: absolutely avoid use in pregnant women; teratogenic risk is category X. Baseline laboratory testing: obtain liver function tests and lipid profile before initiating therapy. Regular monitoring: repeat hepatic and lipid panels periodically during treatment. Avoid vitamin A excess: concurrent high‑dose vitamin A supplements may increase toxicity. Limit sun exposure: use sunscreen and protective clothing to mitigate photosensitivity. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Isotretinoin can interact with several medications, altering its safety or efficacy.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive teratogenic and toxicity risk. - Systemic corticosteroids: may exacerbate mood disturbances. - Anticonvulsants (e.g., phenobarbital, phenytoin): may reduce isotretinoin plasma levels. - Oral retinoids (e.g., acitretin): cumulative teratogenic potential.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy; advise additional contraceptive methods. - Lipid‑lowering agents (e.g., fibrates): possible additive effect on triglycerides. - Antihypertensives: monitor blood pressure as isotretinoin may cause fluid shifts. - Antidepressants: observe for worsening mood symptoms. - NSAIDs: monitor for hepatic enzyme changes.